163 related articles for article (PubMed ID: 34011619)
1. Nuclear-specific accumulation of
Hellgren LS; Olsson A; Kaufeldt A; Paulsson JO; Hysek M; Stenman A; Zedenius J; Larsson C; Höög A; Juhlin CC
J Clin Pathol; 2021 May; 75(10):658-62. PubMed ID: 34011619
[TBL] [Abstract][Full Text] [Related]
2.
Paulsson JO; Mu N; Shabo I; Wang N; Zedenius J; Larsson C; Juhlin CC
Endocr Relat Cancer; 2018 Jul; 25(7):723-733. PubMed ID: 29692346
[TBL] [Abstract][Full Text] [Related]
3. Clinical Routine
Hysek M; Paulsson JO; Jatta K; Shabo I; Stenman A; Höög A; Larsson C; Zedenius J; Juhlin CC
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31561592
[TBL] [Abstract][Full Text] [Related]
4. 5hmC Immunohistochemistry: A Predictor of
Hysek M; Hellgren SL; Condello V; Xu Y; Larsson C; Zedenius J; Juhlin CC
J Histochem Cytochem; 2023 Aug; 71(8):451-458. PubMed ID: 37486076
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
6. Spatial Distribution Patterns of Clinically Relevant TERT Promoter Mutations in Follicular Thyroid Tumors of Uncertain Malignant Potential: Advantages of the Digital Droplet PCR Technique.
Hysek M; Jatta K; Hellgren LS; Stenman A; Larsson C; Zedenius J; Juhlin CC
J Mol Diagn; 2021 Feb; 23(2):212-222. PubMed ID: 33197629
[TBL] [Abstract][Full Text] [Related]
7. Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms.
Proietti A; Sartori C; Macerola E; Borrelli N; Materazzi G; Vitti P; Basolo F
Virchows Arch; 2017 Dec; 471(6):769-773. PubMed ID: 28975450
[TBL] [Abstract][Full Text] [Related]
8. A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!
Juhlin CC
Scand J Surg; 2020 Sep; 109(3):187-192. PubMed ID: 31131695
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours-three examples from the clinical routine.
Hysek M; Paulsson JO; Wang N; Jatta K; Lindh C; Fuentes-Martinez N; Shabo I; Zedenius J; Juhlin CC
Virchows Arch; 2018 Nov; 473(5):639-643. PubMed ID: 29860621
[TBL] [Abstract][Full Text] [Related]
10. Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours.
Marques AR; Espadinha C; Frias MJ; Roque L; Catarino AL; Sobrinho LG; Leite V
Br J Cancer; 2004 Aug; 91(4):732-8. PubMed ID: 15238980
[TBL] [Abstract][Full Text] [Related]
11. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report.
Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC
Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206
[TBL] [Abstract][Full Text] [Related]
12. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization.
Muzza M; Colombo C; Rossi S; Tosi D; Cirello V; Perrino M; De Leo S; Magnani E; Pignatti E; Vigo B; Simoni M; Bulfamante G; Vicentini L; Fugazzola L
Mol Cell Endocrinol; 2015 Jan; 399():288-95. PubMed ID: 25448848
[TBL] [Abstract][Full Text] [Related]
13. GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours.
Paulsson JO; Wang N; Gao J; Stenman A; Zedenius J; Mu N; Lui WO; Larsson C; Juhlin CC
Endocr Relat Cancer; 2020 May; 27(5):295-308. PubMed ID: 32163919
[TBL] [Abstract][Full Text] [Related]
14. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer.
Panebianco F; Nikitski AV; Nikiforova MN; Nikiforov YE
Cancer Med; 2019 Oct; 8(13):5831-5839. PubMed ID: 31408918
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Assessment of
Pestana A; Batista R; Celestino R; Canberk S; Sobrinho-Simões M; Soares P
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32659948
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma.
Na HY; Yu HW; Kim W; Moon JH; Ahn CH; Choi SI; Kim YK; Choi JY; Park SY
Clin Endocrinol (Oxf); 2022 Jul; 97(1):106-115. PubMed ID: 35343605
[TBL] [Abstract][Full Text] [Related]
18. Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR.
Zhao M; Guan Z; Gong L; Liu F; Gu W; Liu L; Jiang K; Cai J; Feng C; Kuick CH; Chang KTE; Wang J; Tang H; Yin M; Mao J
Pathology; 2023 Dec; 55(7):958-965. PubMed ID: 37741703
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylated Mechanistic Target of Rapamycin (p-mTOR) and Noncoding RNA Expression in Follicular and Hürthle Cell Thyroid Neoplasm.
Covach A; Patel S; Hardin H; Lloyd RV
Endocr Pathol; 2017 Sep; 28(3):207-212. PubMed ID: 28660408
[TBL] [Abstract][Full Text] [Related]
20.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
[Next] [New Search]